ARS Pharmaceuticals annual current ratio
2020
2021
2022
2023
2024
2025
ARS Pharmaceuticals Current Ratio Growth & History (SPRY)
ARS Pharmaceuticals's current ratio was 7.28 for fiscal 2025.
View full ARS Pharmaceuticals company overviewARS Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 7.28 | −6.98 | −48.97% |
| 2024 | 2024-12-31 | 14.26 | −82.65 | −85.28% |
| 2023 | 2023-12-31 | 96.92 | 45.91 | +89.99% |
| 2022 | 2022-12-31 | 51.01 | 43.59 | +587.67% |
| 2021 | 2021-12-31 | 7.42 | −33.27 | −81.77% |
| 2020 | 2020-12-31 | 40.69 | — | — |
ARS Pharmaceuticals quarterly current ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.48 | −2.70 | −43.69% |
| Q1 2026 | 2026-03-31 | 4.94 | −6.06 | −55.07% |
| Q4 2025 | 2025-12-31 | 7.28 | −6.98 | −48.97% |
| Q3 2025 | 2025-09-30 | 6.66 | −5.90 | −46.97% |
| Q2 2025 | 2025-06-30 | 6.17 | −26.65 | −81.20% |
| Q1 2025 | 2025-03-31 | 11.00 | −49.90 | −81.94% |
| Q4 2024 | 2024-12-31 | 14.26 | −82.65 | −85.28% |
| Q3 2024 | 2024-09-30 | 12.56 | −9.31 | −42.56% |
| Q2 2024 | 2024-06-30 | 32.82 | 7.46 | +29.40% |
| Q1 2024 | 2024-03-31 | 60.90 | 33.72 | +124.10% |
| Q4 2023 | 2023-12-31 | 96.92 | 45.91 | +89.99% |
| Q3 2023 | 2023-09-30 | 21.87 | −46.00 | −67.78% |
| Q2 2023 | 2023-06-30 | 25.37 | 1.75 | +7.42% |
| Q1 2023 | 2023-03-31 | 27.18 | 9.53 | +53.98% |
| Q4 2022 | 2022-12-31 | 51.01 | 43.59 | +587.67% |
| Q3 2022 | 2022-09-30 | 67.87 | 47.97 | +241.11% |
| Q2 2022 | 2022-06-30 | 23.61 | 0.27 | +1.14% |
| Q1 2022 | 2022-03-31 | 17.65 | −14.98 | −45.91% |
| Q4 2021 | 2021-12-31 | 7.42 | −33.27 | −81.77% |
| Q3 2021 | 2021-09-30 | 19.90 | — | — |
| Q2 2021 | 2021-06-30 | 23.35 | — | — |
| Q1 2021 | 2021-03-31 | 32.63 | — | — |
| Q4 2020 | 2020-12-31 | 40.69 | — | — |
ARS Pharmaceuticals current ratio trends
Over the last five fiscal years, ARS Pharmaceuticals's current ratio decreased from 40.69 to 7.28, a change of −33.41. The latest reported quarter, Q2 2026, shows 3.48.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ARS Pharmaceuticals source filings ↗